Skip to main content
. 2023 Apr 16;12(11):12325–12335. doi: 10.1002/cam4.5931

TABLE 4.

Conversion therapy after Atez/Beva therapy.

Variables N = 156
Conversion therapy (Yes/No) 17/139
Conversion rate 10.9% (17/156)
Surgery 5
RFA 3
TACE 3
Atez/Bev discontinuation 6
Curative therapy (Surgery or RFA) 47.1% (8/17)
Non‐curative therapy 52.9% (9/17)

Abbreviations: Atez/Bev, atezolizumab plus Bevacizumab; RFA, radiofrequency ablation; TACE: transarterial chemoembolization.